Skip to content

    India Pesticides Limited

    IPL
    Chemicals·11 Feb 2025
    Management Summary

    India Pesticides reported a 13% YoY revenue growth to INR175 crores in Q3 FY25, driven by a 30% increase in sales volumes and robust domestic market performance. However, EBITDA margins compressed to 16.7% due to international pricing pressures, elevated freight costs, and strategic investments in R&D and workforce. The company is focused on capacity expansion at Hamirpur, new product development, and operational efficiencies to navigate a volatile market and achieve its future growth and margin targets.

    Highlights

    5
    • Revenue of INR175 crores, up 13% YoY for Q3 FY25.

    • Sales volume increased by around 30% YoY, highlighting product demand.

    • Domestic revenue grew significantly to INR97 crores in Q3 FY25 from INR64 crores in Q3 FY24.

    • Hamirpur plant capacity expansion is on track and expected to start contributing from FY26.

    • Strong balance sheet with ability to generate good free cash flow.

    Concerns

    3
    • EBITDA margin declined to 16.7% in Q3 FY25 due to international pricing adjustments, increased freight costs, and higher R&D/employee expenses.

    • Export revenue decreased to INR75 crores in Q3 FY25 from INR87 crores in Q3 FY24, indicating subdued demand.

    • Inventory days increased to around 170 days due to building inventory for a herbicide product, impacting cash conversion cycle.

    What Changed2

    vs Q4 FY25

    Guidance items7 → 10 (+3)Risks discussed4 → 5 (+1)
    Key financials

    Metrics

    10

    Periods

    2

    Q3 FY25

    7
    • Total Revenue
      ₹175 Cr
      YoY+13%
    • EBITDA
      ₹29 Cr
    • EBITDA Margin
      16.7%
    • Net Profit
      ₹16 Cr
    • PAT Margin
      9.2%

    9M FY25

    3
    • Total Revenue
      ₹633 Cr
      YoY+12%
    • EBITDA
      ₹101 Cr
      YoY+6.3%
    • EBITDA Margin
      15.9%

    Segment breakdown

    • Technicals (Q3 FY25)₹126 Cr73.3%
    • Formulations (Q3 FY25)₹46 Cr26.7%
    Donut· Share of Revenue

    Capital allocation

    2
    high confidence
    CategoryHeadline
    Capex

    ₹50 crores

    More or less from internal accruals; nominal debt for 100% subsidiary in future years if needed.

    Debt

    Debt disclosed

    Guidance & targets

    10
    CategoryTargetPriority
    Profitability
    EBITDA Margin
    16% to 18%
    High
    Revenue
    Revenue Growth
    15% to 20%
    High
    Revenue
    Growth from Existing Operations
    around 10%
    High
    Revenue
    Incremental Growth from Capex
    at least 10%
    High
    Revenue
    Revenue per New Block (Hamirpur)
    INR60 crores to INR70 crores
    High
    Capacity
    Hamirpur Plant Contribution
    start contributing
    High
    Capacity
    Existing Capacity Utilization
    85%
    Medium
    Capex
    New Blocks in Hamirpur
    2 blocks
    High
    Other
    Working Capital Cycle
    decline by 20 days to 25 days
    High
    Market Share
    Export to US Market (share of export turnover)
    around 15%
    High

    What to watch in Q4 FY25

    5

    Hamirpur Plant Commercialization

    FY26 onwards
    CurrentUnder construction, expected to start giving some results
    TargetStart contributing revenue

    Why it matters

    Key driver for future revenue growth and product diversification, indicating successful capex execution.

    Our capex is going on track. We feel that this year, our investment in Hamirpur plant should start giving us some results. And from next year onwards, it will give full results...

    Risks & concerns

    5
    RiskSeverity

    Export Market Volatility & Price Pressure

    Export demand remains constrained due to persistent price volatility, market oversupply, and margin pressures, leading to a 15% YoY price decline in Q3 FY25.Management acknowledged

    high

    Increased Freight Costs

    Freight costs rose due to logistical challenges in the Red Sea region, contributing to margin compression.Management acknowledged

    medium

    Higher Operating Expenses (R&D, Employee)

    Investment in strengthening R&D capabilities and workforce (new personnel) added to the cost base, impacting EBITDA margins.Management acknowledged

    medium

    Global Geopolitical/Trade Tensions

    Threats of tariffs from the U.S. President are complicating the global situation and impacting confidence in pricing.Both acknowledged

    medium

    Short-Term Customer Commitments

    Market volatility leads large customers to commit for only 1-2 months rather than 6-12 months, requiring adaptive planning.Management acknowledged

    medium

    Q&A highlights

    8

    “The export market demand is more or less stable. We are getting demand inquiries, but the prices are slightly subdued. That is the situation now. And we are trying to increase our efficiency to meet those prices.”

    Clarifies the ongoing pricing pressure in export markets and the slight stabilization QoQ, with management focusing on efficiency.

    asked by Ankit Gupta

    2 min read6 chapters

    Detailed Narrative

    01

    Q3 FY25 Performance and 9M Overview

    India Pesticides reported a 13% year-on-year revenue growth in Q3 FY25, achieving a total income of INR175 crores, driven by a 30% increase in sales volumes. Domestic revenue significantly increased to INR97 crores from INR64 crores in Q3 FY24, while export revenue saw a decline to INR75 crores from INR87 crores. For the nine months of FY25, total revenue reached INR633 crores, marking a 12% increase, with EBITDA growing by 6.3% to INR101 crores, resulting in an EBITDA margin of 15.9%.

    02

    Margin Compression and Cost Factors

    Despite revenue growth, the EBITDA margin for Q3 FY25 stood at 16.7%, impacted by several factors. Pricing adjustments in the international market, increased freight costs due to logistical challenges in the Red Sea region, and higher employee expenses for R&D and workforce strengthening contributed to the margin decline. The company noted that while gross margins remained stable, these operational and strategic investments added to the overall cost base.

    03

    Market Dynamics and Pricing Environment

    The agrochemical industry continues to navigate a dynamic environment, with export demand constrained by persistent price volatility and market oversupply, particularly from China. Management indicated that prices are subdued, with a 15% YoY decline in Q3 FY25, following a 20% decline in the previous quarter. Current prices are significantly below 2019 pre-COVID levels, with some products experiencing declines of over 50%, prompting the company to focus on efficiency to meet these price points.

    04

    Strategic Capacity Expansion and New Product Focus

    India Pesticides is progressing with its capacity expansion plans, especially at its Hamirpur facility, which is expected to start contributing revenue from FY26. An annual capex of around INR50 crores is planned for Hamirpur, with 2 new blocks scheduled for construction in FY26 as part of a larger plan for 10-12 blocks. These new facilities will focus on adding new products and intermediates, including one insecticide and one herbicide, to diversify the product portfolio and avoid duplicating existing Sandila offerings. Registration work for these new molecules is actively underway.

    05

    Working Capital and Inventory Management

    The company's cash conversion cycle has extended, with inventory days increasing to approximately 170 days. This rise is attributed to a strategic decision to build inventory for a high-selling herbicide product in preparation for the upcoming Kharif season. Management anticipates an improvement in the working capital cycle, projecting a reduction of 20-25 days from the March quarter onwards as the accumulated inventory is sold in Q4.

    06

    Outlook and Future Growth Targets

    India Pesticides aims to maintain its EBITDA margins within the range of 16% to 18% in the coming quarters and targets a revenue growth of 15% to 20% for the next year. This growth is expected to be driven by a combination of approximately 10% from existing operations and at least 10% incremental growth from the ongoing capex projects. The company also expects to improve its current capacity utilization from 60% to 85% if international market demand shows signs of recovery.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.